2025-07-08 - Analysis Report
Okay, here's a comprehensive analysis of TG Therapeutics Inc. (TGTX), incorporating the provided data and presented in English with numerical summaries and concise analysis.

## TG Therapeutics Inc. (TGTX) Analysis

**0. Overview**

This report provides a summary and analysis of TG Therapeutics Inc. (TGTX) based on the data provided.

**1. Performance vs. S&P 500 (VOO)**

*   **Ticker:** TGTX
*   **Company Description:** TG Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.

*   **Key Metrics:**
    *   TGTX Cumulative Return: 63.15%
    *   VOO Cumulative Return: 95.42%
    *   Absolute Divergence: -32.27% (63.15% - 95.42%)
    *   Divergence Range: Max 401.1, Min -110.5
    *   Current Divergence: -36.1
    *   Relative Divergence: 14.5 (Indicates the current divergence is near the lower end of its historical range relative to VOO)

*   **Alpha/Beta Analysis:**

    | Year       | CAGR   | MDD   | Alpha   | Beta   | Cap(B) |
    | :----------- | :----- | :----- | :------ | :----- | :----- |
    | 2015-2017  | -6.0%  | 56.5% | -35.0% | -0.1 | 1.3    |
    | 2016-2018  | -8.0%  | 58.6% | -26.0% | 0.0  | 0.6    |
    | 2017-2019  | 74.0%  | 58.6% | 44.0%  | 0.0  | 1.7    |
    | 2018-2020  | 402.0% | 58.6% | 382.0% | -0.4 | 8.1    |
    | 2019-2021  | 125.0% | 63.5% | 76.0%  | -0.5 | 3.0    |
    | 2020-2022  | -76.0% | 70.4% | -78.0% | -0.6 | 1.8    |
    | 2021-2023  | -350.0% | 70.4% | -368.0% | -0.8 | 2.7    |
    | 2022-2024  | 71.0%  | 73.1% | 45.0%  | -0.9 | 4.7    |
    | 2023-2025  | 70.0%  | 73.1% | 23.0%  | 0.4  | 5.7    |

*   **Analysis:**
    *   TGTX has underperformed VOO cumulatively.
    *   The relative divergence suggests that while TGTX is lagging, its performance is not unusual compared to its historical behavior against VOO.
    *   Alpha is largely negative, suggesting the stock consistently underperforms the benchmark even when considering market-related movements, and Beta values have fluctuated.
    *   The high positive Alpha and CAGR in 2018-2020 are an outlier.
    *   The high MDD values indicate significant volatility.

**2. Recent Price Action**

*   **Current Price:** \$36.72
*   **Last Market Data:**
    *   Price: \$35.995
    *   Previous Close: \$36.72
    *   Change: -1.97% (Significant decrease from previous close, indicating negative momentum)
*   **Moving Averages:**
    *   5-day MA: \$36.286
    *   20-day MA: \$37.1323
    *   60-day MA: \$37.0905

*   **Analysis:**
    *   The recent price drop and the fact that the current price is below all three moving averages suggest short-term downward pressure. The 5-day MA is below the 20-day and 60-day, further confirming this trend.

**3. Technical Indicators & Expected Return**

*   **Market Risk Indicator (MRI):** 0.3301 (Low Risk)
*   **RSI:** 46.49 (Neutral - neither overbought nor oversold)
*   **PPO:** -0.1046 (Slightly negative, suggesting a weak downward trend)
*   **Hybrid Signal:** "cash\_1% Buy 80% of cash (127 shares - Caution - MRI:0.33) (Cash Ratio: 1% on 2025-06-27)" - This signal suggests a cautious buy signal, with a significant portion of available cash being allocated, but also highlights caution due to the Market Risk Indicator.
*   **Recent (20-day) Relative Divergence Change:** -1.5 (Negative, confirming short-term decline relative to the benchmark)
*   **Expected Return:** -274.0% (Significantly negative, indicating a highly pessimistic outlook relative to the S&P 500 over the long term)

*   **Analysis:**
    *   The MRI indicates a relatively low-risk market environment, but other indicators paint a more cautious picture.
    *   The significantly negative expected return is a major red flag, suggesting that the model predicts substantial underperformance compared to the S&P 500 if a long-term investment is made at this point.
    *   The large price change from the previous close (-1.97%) is important and shows potential volatility and downward trend.

**4. Recent News & Significant Events**

*   **[2025-07-06]:** TG Therapeutics Inc (TGTX) has recently made headlines due to major business developments, regulatory changes, or market events.
*   **[2025-07-08]:** Analysts are discussing TG Therapeutics Inc's (TGTX) recent performance and its outlook in the context of industry trends and global economic factors.
*   **[2025-07-05]:** TG Therapeutics Inc (TGTX)'s stock has shown notable volatility, influenced by recent news, earnings reports, or executive actions.
*   **[2025-07-07]:** Market experts highlight both risks and opportunities for TG Therapeutics Inc (TGTX), advising investors to monitor recent news and company announcements.

*   **Analysis:** The news highlights recent activity, suggesting potential catalysts driving price movements. Volatility is noted, requiring careful monitoring of company announcements and market reactions.

**5. Recent Earnings Analysis**

| 날짜       | EPS    | 매출     |
| :--------- | :----- | :------- |
| 2025-05-09 | 0.03   | 0.12 B\$ |
| 2024-11-07 | 0.03   | 0.08 B\$ |
| 2024-08-09 | 0.05   | 0.07 B\$ |
| 2024-05-06 | -0.07  | 0.06 B\$ |
| 2025-05-09 | -0.07  | 0.06 B\$ |

*   **Analysis:**
    *   Earnings per share (EPS) has fluctuated.
    *   Revenue has generally increased over the last several quarters.

**6. Financial Information**

*   **Revenue and Profitability:**

    | Quarter    | Revenue    | Profit Margin |
    | :--------- | :--------- | :------------ |
    | 2025-03-31 | \$0.12B   | 87.14%        |
    | 2024-12-31 | \$0.11B   | 85.77%        |
    | 2024-09-30 | \$0.08B   | 88.86%        |
    | 2024-06-30 | \$0.07B   | 88.70%        |
    | 2024-03-31 | \$0.06B   | 91.43%        |

*   **Capital and Profitability:**

    | Quarter    | Equity     | ROE      |
    | :--------- | :--------- | :------- |
    | 2025-03-31 | \$0.24B   | 2.13%    |
    | 2024-12-31 | \$0.22B   | 10.49%   |
    | 2024-09-30 | \$0.19B   | 2.02%    |
    | 2024-06-30 | \$0.18B   | 3.87%    |
    | 2024-03-31 | \$0.16B   | -6.69%   |

*   **Analysis:**
    *   Revenue is trending upwards.
    *   Profit margins are very high and relatively stable.
    *   Equity is increasing.
    *   ROE has fluctuated but generally shows improvement.

**7. Overall Analysis & Conclusion**

Based on the provided data, TG Therapeutics Inc. (TGTX) presents a mixed picture.

*   **Negatives:**
    *   Underperformance compared to the S&P 500.
    *   Significantly negative expected return.
    *   Recent price decline below key moving averages.
    *   Fluctuating EPS and negative EPS in recent periods.
    *   High volatility (MDD).

*   **Positives:**
    *   Increasing revenue and high profit margins.
    *   Growing equity.
    *   Low Market Risk Indicator (MRI).
    *   Recent News indicating potential positive changes/events.

**Overall Recommendation:** The data suggests a cautious approach. While revenue growth and high profit margins are positive, the underperformance relative to the S&P 500 and the extremely negative expected return raise significant concerns. The recent price decline and negative divergence further contribute to the cautious outlook. The recent news indicates potential positive drivers, but it needs to be carefully followed.

**Disclaimer:** This is an AI-generated analysis based on the provided data and should not be considered financial advice. Conduct thorough research and consult with a qualified financial advisor before making any investment decisions.
